Wells Fargo raised the firm’s price target on Cerevel Therapeutics (CERE) to $45 from $30 and keeps an Equal Weight rating on the shares. The firm cites AbbVie’s (ABBV) announcement that it will acquire Cerevel for $8.7B or $45 per share. The deal is expected to close mid-2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CERE: